Results 131 to 140 of about 76,496 (274)

Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials [PDF]

, 1999
Solko W. Schalm, Ola Weiland, Bettina E. Hansen, Michele Stanislaw Milella, Ming Y. Lai, A. Gerson Hollander, P. Michielsen, Antonio Bellobuono, Liliana Chemello, Giuseppe Pastore, Ding‐Shinn Chen, Johannes T. Brouwer   +11 more
openalex   +1 more source

Sustained response to interferon‐α or to interferon‐α plus ribavirin in hepatitis C virus‐associated symptomatic mixed cryoglobulinaemia [PDF]

, 1999
Calleja, Albillos Albillos, Moreno‐Otero, Rossi, Cacho, Domper, Yebra, Escartín   +7 more
openalex   +1 more source

Double-Blind Evaluation of Oral Ribavirin (Virazole) in Experimental Influenza A Virus Infection in Volunteers

, 1978

openalex   +1 more source

Synergistic anti-influenza virus A (H1N1) activities of PM-523 (polyoxometalate) and ribavirin in vitro and in vivo [PDF]

, 1997
Shirô Shigeta, Shunsuke Mori, Junko Watanabe, Shu Soeda, Kazuo Takahashi, Toshihiro Yamase   +5 more
openalex   +1 more source

Market uptake of pegylated interferons for the treatment of hepatitis C in Europe : meeting abstract [PDF]

, 2008
Introduction and Objectives Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease with life threatening sequelae such as end-stage liver cirrhosis and liver cancer.
Lettmeier, Beate, Mühlberger, Nikolai, Schwarzer, Ruth, Siebert, Uwe, Sroczynski, Gaby, Zeuzem, Stefan   +5 more
core  

Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis

Clinical and Experimental Gastroenterology, 2012
Eric Druyts1, Edward J Mills1,2, Jean Nachega3, Christopher O'Regan4, Curtis L Cooper51Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada; 2Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON,
O'Regan C, Nachega J, Mills EJ, Druyts E, Cooper CL   +4 more
doaj  

PROSPECTIVE (7YRS) FOLLOW UP (FU) AND PULMONARY FUNCTIONS (PFT) FROM A PLACEBO (P) CONTROLLED RANDOMIZED TRIAL OF RIBAVIRIN (R) IN RSV BRONCHIOLITIS(B). ▴ 1086 [PDF]

, 1996
William J. Rodriquez, Julie Arrobio, Robert Fink, Hyun W Kim, Cherye Milburn   +4 more
openalex   +1 more source

Impact of a treatment as prevention strategy on hepatitis C virus transmission and on morbidity in people who inject drugs [PDF]

, 2015
Background: Highly effective direct-acting antiviral (DAA) regimens (90% efficacy) are becoming available for hepatitis C virus (HCV) treatment. This therapeutic revolution leads us to consider possibility of eradicating the virus.
Cousien, Anthony, Deuffic-Burban, Sylvie, Dhersin, Jean-Stéphane, Jauffret-Roustide, Marie, Tran, Viet Chi, Yazdanpanah, Yazdan   +5 more
core   +3 more sources

Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro

, 1987
Masanori Baba, Rudi Pauwels, Jan Balzarini, Piet Herdewijn, Erik De Clercq, Jan Desmyter   +5 more
openalex   +1 more source

PRECIPITATION OF RIBAVIRIN CAUSING OBSTRUCTION OF A VENTILATION TUBE

, 1986
Ralph A. Hicks, Lloyd C. Olson, Mary Anne Jackson, V. Fred Burry   +3 more
openalex   +1 more source